EVP, Chief Operating Officer · SAB Biotherapeutics, Inc. (SABS)

Christoph Bausch

A named executive officer of SAB Biotherapeutics in every fiscal year CompBrief holds from FY2022 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,682,520

Salary $425,000

FY2024: $1,196,747

5th of 5 named executive officers at SAB Biotherapeutics by FY2025 total.

5 named officers on file for SAB Biotherapeutics, FY2025

Christoph Bausch’s pay file — $29

  • 4 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how SAB Biotherapeutics’s whole pay program stands against its peers

  • SAB Biotherapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SABS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2026 (DEF 14A).

Free

Get Christoph Bausch’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Christoph Bausch compensation by year

SAB Biotherapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as SAB Biotherapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024FY2025
Salary$308,855$325,000$412,200$425,000
Bonus$0$0——
Stock awards$0$0——
Option awards$184,551$106,123$622,162$1,073,520
Non-equity incentive$50,445$105,000$150,000$170,000
Pension and deferred compensation$0$0——
All other$12,200$13,200$12,385$14,000
Total$556,051$549,323$1,196,747$1,682,520

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SAB Biotherapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-197607, and prior-year filings. Open the filing on EDGAR.

How this page was built: the SAB Biotherapeutics, Inc. filed document, accession 0001193125-26-197607. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

$556K
$549K
$1.2M
$1.7M
FY22
FY23
FY24
FY25
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option8,594—$5.35
Option600,000—$2.17
Option75,834—$5.17
Option18,890—$2.90
Option5,154—$7.11

Per the Outstanding Equity Awards at Fiscal Year-End table in SAB Biotherapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

SAB Biotherapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Samuel ReichChief Executive Officer$9,434,622
Eddie SullivanPresident$6,114,100
Alexandra KropotovaEVP, Chief Medical Officer$5,126,279
Lucy ToEVP, Chief Financial Officer$2,831,074
Christoph Bausch · this pageEVP, Chief Operating Officer$1,682,520

The full SAB Biotherapeutics compensation record

free company brief

This page is one person within SAB Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SAB Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Christoph Bausch's compensation dossier · One-time report. No refunds.